What Is the CBD Dosing Required for Effective Pain Relief ? Damian McNamara, CME, Laurie Barclay, MD Posted: 12/14/2018 Clinical Context The effects of cannabis in humans include euphoria, increased sensitivity to external experience, relaxation, and potential for addiction. Cannabidiol is a compound in the cannabis plant that lacks euphoric and addictive qualities and that may be useful to treat conditions including chronic pain, nausea, epilepsy, psychosis, and anxiety. The optimal therapeutic dose of CBD has not yet been determined, and it has been used in a wide dose range from 2.85 to 50 mg/kg/day. The therapeutic effects of CBD appear to emanate from its interaction [...]
Lire la suiteCannabidiol (CBD) : analyse de situation Frank ZOBEL, Luca NOTARI, Eva SCHNEIDER, Ocyna RUDMANN Addiction Suisse, Lausanne, janvier 2019 Rapport de recherche N° 97 https://www.addictionsuisse.ch/fileadmin/user_upload/DocUpload/Rapport-CBD-final.pdf Table des matières Liste des tableaux Liste des graphiques 1 Introduction 2 Méthode 3 Brève analyse de la littérature sur les effets du Cannabidiol (CBD) 3.1 Méthode 3.2 Usages du CBD et effets 3.3 Pourquoi prendre du CBD? Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine somatique Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine psychique Traitement/prévention de maladies chroniques et neurodégénératives, renforcement du système immunitaire . Traitement de troubles neurologiques diagnostiqués . Autres 3.4 Que sait-on de ces effets à ce jour? 3.5 Le CBD peut-il [...]
Lire la suiteA Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain Griffin A. TYREE, Reith SARKAR, Brandon K. BELLOWS, Ronald J. ELLIS, Joseph HAMPTON ATKINSON, Thomas D. MARCOTTE, Mark S. WALLACE, Igor GRANT, Yuyan SHI, James D. MURPHY, and David J. GRELOTTI Cannabis and Cannabinoid Research, Volume 0, Number 0, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0027 Abstract Background : A recent meta-analysis affirmed the benefit of medicinal cannabis for chronic neuropathic pain, a disabling and difficult-to-treat condition. As medicinal cannabis use is becoming increasingly prevalent among Americans, an exploration of its economic feasibility is warranted. We present this cost-effectiveness analysis of adjunctive [...]
Lire la suiteMedicinal Properties of Cannabis, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain : An Update on Current Evidence and Cannabis Science, Eric P. BARON Headache, July/August 2018, 1139-1186. Background.—Comprehensive literature reviews of historical perspectives and evidence supporting cannabis/ cannabinoids in the treatment of pain, including migraine and headache, with associated neurobiological mechanisms of pain modulation have been well described. Most of the existing literature reports on the cannabinoids Δ9- tetrahydrocannabinol (THC) and cannabidiol (CBD), or cannabis in general. There are many cannabis strains that vary widely in the composition of cannabinoids, terpenes, flavonoids, and other compounds. These components work [...]
Lire la suiteMedical cannabis : An oxymoron ? Physicians’ perceptions of medical cannabis Yuval ZOLOTOVA, Simon VULFSONS, Dana ZARHIN, Sharon SZNITMAN International Journal of Drug Policy, 2018, 57, 4-10. A B S T R A C T : Background : Medical cannabis policies are changing in many places around the world, and physicians play a major role in the implementation of these policies. The aim of this study was to gain a deeper understanding of physicians’ views on medical cannabis and its possible integration into their clinic, as well as to identify potential underlying factors that influence these perceptions. Methods : Qualitative narrative analysis of in-depth interviews [...]
Lire la suiteCannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report Amanda REIMAN, Mark WELTY, Perry SOLOMON Cannabis and Cannabinoid Research, 2017, Vol 2, n°1 Abstract Introduction: Prescription drug overdoses are the leading cause of accidental death in the United States. Alternatives to opioids for the treatment of pain are necessary to address this issue. Cannabis can be an effective treatment for pain, greatly reduces the chance of dependence, and eliminates the risk of fatal overdose compared to opioid-based medications. Medical cannabis patients report that cannabis is just as effective, if not more, than opioid-based medications for pain. Materials and Methods: The current study examined the [...]
Lire la suiteAdverse effects of medical cannabinoids : a systematic review T. Wang, J-P. Collet, S. Shapiro, M.A. Ware, Canadian Medical Association Journal, 2008,178,13, 1669-1678 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/pdf/20080617s00017p1669.pdf Abstract Background : The therapeutic use of cannabis and cannabisbased medicines raises safety concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most safety information comes from studies of recreational use. Methods : We performed a systematic review of safety studies of medical cannabinoids published over the past 40 years to create an evidence base for cannabis-related adverse events and to facilitate future cannabis research initiatives. We critically evaluated [...]
Lire la suitehttps://www.ncbi.nlm.nih.gov/books/NBK425767/ The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US); 2017 Jan 12. ISBN-13: 978-0-309-45304-2ISBN-10: 0-309-45304-6 Copyright and Permissions Hardcopy Version at National Academies Press Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for [...]
Lire la suitehttps://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) Plante séchée ou fraîche et huile destinées à l'administration par ingestion ou par d'autres moyens Agent psychoactif Le présent document a été préparé par la Direction générale de la légalisation et réglementation du cannabis de Santé Canada pour fournir des renseignements sur l'usage du cannabis (marihuana) et des cannabinoïdes à des fins médicales. Le présent document est un résumé d'articles scientifiques examinés par les pairs et de revues internationales sur les utilisations thérapeutiques possibles et sur les effets néfastes du cannabis et des [...]
Lire la suiteBibliographie CANNABINOÏDES et Douleurs Neuropathiques Dr Christian SUEUR, GRECC, octobre 2018. ABRAMS D.I. et al. : Short-term effects of cannabinoids in patients with HIV-1 infection : a randomized, placebo-controlled clinical trial, Annals of Internal Medicine, 2003, 139, 4, 258-266. ABRAMS D.I., JAY C.A., SHADE S.B. et al. : Cannabis in painful HIV-associated sensory neuropathy : a randomized placebo-controlled trial, Neurology, 2007, 68, 515-521. DOI : 10.1212/01.wnl.0000253187.66183.9c ABRAMS D.I., COUEY P., SHADE S.B., KELLY M.E., BENOWITZ N.L. : Cannabinoid-Opioid Interaction in chronic Pain, Clinical Pharmacology & Therapeutics, 2011, 90, 6, 844-51. DOI : 10.1038/CLPT.2011.188 AGGARWAL S.K., CARTER G.T., SULLIVAN M.D. et al. : Medicinal use of cannabis in the United [...]
Lire la suite